Robert S Epstein
Overview
Explore the profile of Robert S Epstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1584
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zeidan A, Perepezko K, Salimi T, Washington T, Epstein R
Ther Adv Hematol
. 2024 Aug;
15:20406207241257313.
PMID: 39091323
Background: Hypomethylating agents (HMAs) are guideline-recommended treatment for higher-risk myelodysplastic syndromes/neoplasms (MDS). However, survey of patients with MDS reported challenges with intravenous (IV) and subcutaneous (SC) HMA therapies, including pain...
2.
Goyal L, Meric-Bernstam F, Hollebecque A, Valle J, Morizane C, Karasic T, et al.
Future Oncol
. 2024 Jun;
20(36):2811-2822.
PMID: 38884254
What Is This Summary About?: This summary describes the results from a phase 2 study called FOENIXCCA2. The study evaluated treatment with futibatinib in people with a rare form of...
3.
Goyal L, Meric-Bernstam F, Hollebecque A, Valle J, Morizane C, Karasic T, et al.
N Engl J Med
. 2023 Jan;
388(3):228-239.
PMID: 36652354
Background: Alterations in fibroblast growth factor receptor 2 () have emerged as promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor prognosis. Futibatinib, a next-generation, covalently binding...
4.
Zeidan A, Joshi N, Kale H, Wang W, Corman S, Salimi T, et al.
Clin Lymphoma Myeloma Leuk
. 2022 May;
22(9):670-679.
PMID: 35614009
Background: Previous analyses using the SEER-Medicare database have reported substantial underutilization of hypomethylating agents (HMAs) among patients with higher-risk myelodysplastic syndromes (MDS), and an association between poor HMA persistence and...
5.
Epstein R, Nelms J, Moran D, Girman C, Huang H, Chioda M
Cancer Treat Res Commun
. 2022 Apr;
31:100555.
PMID: 35421820
Purpose: To depict the treatment journey for patients with small cell lung cancer (SCLC) and evaluate health care resource utilization (HCRU) associated with myelosuppression, a complication induced by chemotherapy or...
6.
Harvey M, Zhong Y, Morris E, Beverage J, Epstein R, Chawla A
PLoS One
. 2022 Jan;
17(1):e0261336.
PMID: 35073335
Subcutaneous (SC) administration of rituximab provides an opportunity for reduced patient treatment burden and increased healthcare efficiencies as an alternative to intravenous (IV) rituximab. There is minimal evidence comparing costs...
7.
Epstein R, Weerasinghe R, Parrish A, Krenitsky J, Sanborn R, Salimi T
J Med Econ
. 2021 Dec;
25(1):108-118.
PMID: 34927520
Aims: Chemotherapy-induced myelosuppression, which commonly exhibits as neutropenia, anemia, or thrombocytopenia, represents a substantial burden for patients with cancer that affects health-related quality of life and increases healthcare resource utilization...
8.
Zeidan A, Salimi T, Epstein R
Future Oncol
. 2021 Oct;
17(36):5163-5175.
PMID: 34636250
Myelodysplastic syndromes are hematological malignancies characterized by ineffective hematopoiesis and a high risk of progression to acute myeloid leukemia. Hypomethylating agents (HMAs), azacitidine and decitabine, are standard of care therapy...
9.
Epstein R
Clinicoecon Outcomes Res
. 2021 Sep;
13:801-807.
PMID: 34531668
The coronavirus disease 2019 (COVID-19) pandemic has brought increased attention to vulnerable populations such as older or immunocompromised patients and heightened the focus on alternatives to intravenous (IV) formulations, particularly...
10.
Gold D, Weiss R, Beckett T, Deal C, Epstein R, James A, et al.
JBMR Plus
. 2021 Mar;
5(3):e10457.
PMID: 33778325
Despite the availability of various osteoporosis treatments, adherence remains suboptimal. One contributing factor may be patient experience with therapy. This US, multicenter, combined retrospective chart review and patient questionnaire study...